.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Cantor Fitzgerald
UBS
Johnson and Johnson
Chubb
Fish and Richardson
Colorcon
QuintilesIMS
Cerilliant

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Stabilized antihistamine syrup
Abstract:An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.
Inventor(s): Munayyer; Farah J. (West Caldwell, NJ), Guazzo; Frank (Bridgewater, NJ), Stupak; Elliot I. (West Caldwell, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Sequeira; Joel A. (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Filing Date:Nov 15, 2002
Application Number:10/298,175
Claims:1. A syrup formulation containing an antihistaminic amount of azatadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

2. The syrup of claim 1, wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

3. The syrup of claim 1, wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

4. The syrup of claim 1, in which the aminopolycarboxylic acid comprises about 0.1 to about 1 mg/mL.

5. The syrup of claim 1, in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

6. The syrup of claim 1, further containing a therapeutically effective amount of a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more thereof.

7. The syrup of claim 1, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

8. The syrup of claim 1, further containing the decongestant pseudoephedrine.

9. An antihistaminic syrup formulation containing azatadine and about 0.05 to about 5 mg/mL of a sodium salt of ethylenediaminetetraacetic acid.

10. The syrup of claim 9, which the salt of ethylenediaminetetraacetic acid comprises about 0.1 to about 1 mg/mL.

11. The syrup of claim 9, in which the salt of ethylenediaminetetraacetic acid comprises about 0.25 to about 0.5 mg/mL.

12. The syrup of claim 9, further containing an analgesic.

13. The syrup of claim 9, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

14. An antihistaminic syrup formulation containing azatadine and about 0.05 to about 5 mg/mL of the disodium salt of ethylenediaminetetraacetic acid.

15. The syrup of claim 14, in which the disodium salt of ethylenediaminetetraacetic acid comprises about 0.1 to about 1 mg/mL.

16. The syrup of claim 14, in which the disodium salt of ethylenediaminetetrascetic acid comprises about 0.25 to about 0.5 mg/mL.

17. The syrup of claim 14, further containing an analgesic.

18. The syrup of claim 14, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

19. The syrup of claim 18, further containing an analgesic.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Citi
Harvard Business School
Healthtrust
Dow
Fuji
Queensland Health
QuintilesIMS
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot